ReviewOncoTargets and therapy2017
Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?
Review in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances.Current oncology reports · 2024Review
- Best practices in surgical and nonsurgical management of head and neck Merkel cell carcinoma: An update.Molecular carcinogenesis · 2023Article
- Therapeutic Potential of 5'-Methylschweinfurthin G in Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma.Viruses · 2022Article
- Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?International journal of molecular sciences · 2021Review
- Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.The oncologist · 2019Review
- Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma.BMJ case reports · 2019Article
- Paraneoplastic cerebellar ataxia in Merkel cell carcinoma of unknown primary.JAAD case reports · 2019Article
- Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions.Journal of cancer research and clinical oncology · 2019Review
- Burden of Disease, Early Diagnosis, and Treatment of Merkel Cell Carcinoma in Latin America.Journal of global oncology · 2018Review
- Advances in Immunology: A Cornerstone in Diagnosis and Therapy of Merkel Cell Carcinoma.Journal of investigative medicine high impact case reportsArticle
- Complete remission of atypical Merkel cell carcinoma of eyelid with parotid gland and lymph node metastasis through chemotherapy.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although cytotoxic chemotherapy has been used often in the management of Merkel cell carcinoma (MCC), its benefit remains uncertain. Despite being considered a chemosensitive disease, the duration of response is generally short, and the survival benefit is unclear. With the recent FDA approval of the anti-programmed cell death ligand 1 (PD-L1) antibody avelumab for patients with advanced MCC and the limited and controversial data on chemotherapy, it is important to put in perspective whether conventional chemotherapy should remain an option for these patients. Here, we review the evidence and controversies around chemotherapy in MCC as well as two recent studies on immunotherapy that changed the treatment paradigm for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.